ISRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intuitive Surgical Inc (ISRG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial growth, positive congressional trading sentiment, and favorable analyst upgrades outweigh the short-term technical weakness and insider selling. Given the investor's preference for long-term growth, ISRG's position as a leader in medical robotics and its consistent revenue and EPS growth make it a solid choice.
The technical indicators suggest a bearish short-term trend. The MACD is negatively expanding (-0.679), the RSI is neutral at 26.053, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support levels are at $462.31 and $453.713, while resistance levels are at $490.143 and $498.74.
Strong financial performance in Q4 2025 with revenue up 18.76% YoY, net income up 15.91% YoY, and EPS up 17.55% YoY.
Positive congressional trading sentiment with $1.5M-$5.0M in recent purchases.
Analyst upgrades, including Citi's Buy rating with a $590 target and TD Cowen's Buy rating with a $660 target, citing strong growth potential.
Industry leadership in medical robotics and innovation, supported by the rollout of the da Vinci 5 system.
Insider selling has increased by 184% over the last month, signaling potential concerns from company insiders.
Short-term technical indicators are bearish, with MACD and moving averages showing weakness.
UBS and Evercore ISI have lowered price targets recently, reflecting some caution among analysts.
In Q4 2025, ISRG reported strong financial growth: Revenue increased by 18.76% YoY to $2.87 billion, net income rose by 15.91% YoY to $794.8 million, and EPS grew by 17.55% YoY to $2.21. However, gross margin declined slightly to 66.44%, down 2.35% YoY, indicating some cost pressures.
Analyst sentiment is mixed to positive. Recent upgrades include Citi's Buy rating with a $590 price target and TD Cowen's Buy rating with a $660 price target. UBS and Evercore ISI have lowered price targets but maintained Neutral or In Line ratings. Overall, analysts view ISRG as a strong long-term growth story in the medical technology sector.
